Skip to content
My WebMD Sign In, Sign Up

COPD Health Center

Font Size

Combo Treatment Works Best for COPD

Only Small Benefit Seen With Chronic Obstructive Pulmonary Disease Treatment
By
WebMD Health News
Reviewed by Louise Chang, MD

Feb. 21, 2007-- A promising treatment for chronic obstructive pulmonary disease (COPD) failed to show a clear survival benefit in a large international trial, but improvements were seen in patient lung function and overall health.

The study looked at treatment with Advair Diskus 500/50, which combines an inhaled corticosteroid (Flovent) and a long-acting beta-agonist (Serevent).

Researchers compared treatment with the combination drug Advair with each of the therapies alone, and with no treatment, in patients with chronic obstructive pulmonary disease.

Compared with untreated patients, Advair-treated patients were 17.5% less likely to die of all causes during the three-year study.

While the reduction fell just short of reaching statistical significance, the trial’s author tells WebMD he believes the combined therapy can help patients live longer.

The study is published in the Feb. 22 issue of The New England Journal of Medicine.

“We came very close [to showing a survival advantage], but we didn’t quite make it,” says Peter M.A. Calverley, MD.

“We clearly showed that the combined treatment helps prevent disease-related exacerbations and helps people feel better," he says. "But does it help them live longer? We can’t say for sure; but we think it does.”

A Leading Killer

COPD, which includes emphysema and chronic bronchitis, is the fourth leading cause of death in the U.S.

The disease hampers the airflow of the airways, making it hard to breathe.  It generally worsens over time.

Nearly 11 million American have been diagnosed with COPD, but it is widely believed millions more may have it.

The international study, known as the TORCH trial, included 6,112 patients in 42 countries who had moderate to severe COPD.

Roughly a quarter of the patients took Advair, which contains the corticosteroid, fluticasone propionate, and a long-acting beta-antagonist, salmeterol.

The remaining patients were treated with either the inhaled corticosteroid alone, the long-acting beta-agonist alone, or a placebo.

Beta-agonists like salmeterol work by relaxing the smooth muscles of the airways, which improves airflow.

Inhaled corticosteroids reduce inflammation, which is thought to play a role in COPD.

Study Results

A total of 875 patients died during the three-year study.

Deaths from all causes occurred in 12.6% of the combination treatment group, 13.5% of the group treated with the long-acting beta-agonist alone, 16% of those treated with the inhaled corticosteroid alone, and 15.2% of the placebo group.

Compared with no treatment, the combination treatment resulted in statistically meaningful improvements in lung function and less worsening of COPD-related symptoms.

Treatment with inhaled corticosteroids -- either alone or as part of the combination therapy -- was associated with an increase in pneumonia in the newly reported study.

Patients treated with either the combination therapy or the inhaled steroids alone were 60% more likely to be diagnosed with pneumonia.  But, surprisingly, they were no more likely to die or be hospitalized than patients who did not receive corticosteroids.

“We don’t really know what this means,” Calverley says. “These patients had more pneumonias, but on average they felt better and had fewer flare-ups of their disease than [untreated] patients.”

Today on WebMD

chest x-ray
SLIDESHOW
Lung Disease Health Check
HEALTH CHECK
 
man smoking cigarette
Article
man with inhaler
Quiz
 
Bronchitis Overview
Article
Senior woman blowing dandelion
ARTICLE
 
Living With Copd
VIDEO
human lung graphic
Article
 
Energy Boosting Foods
Slideshow
lung cancer overview slideshow
Article
 
mature man coughing
Article
Senior couple stretching
Slideshow